View Older Stories View More Recent Stories

Apr 3, 2018 01:00AM European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Mar 23, 2018 08:48AM Amgen (AMGN), Allergan (AGN) Receive Positive CHMP Opinion For ABP 980 For Treatment of Three Types Of Cancer
Mar 23, 2018 08:46AM Amgen (AMGN) Announces Positive CHMP Opinion Recognizing That Repatha Prevents Heart Attacks And Strokes
Mar 23, 2018 08:44AM Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes
Mar 23, 2018 08:41AM Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer
Mar 9, 2018 09:00AM New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events
Mar 7, 2018 04:15PM Amgen Announces 2018 Second Quarter Dividend
Mar 7, 2018 04:00PM Amgen To Present At the Cowen and Company 38th Annual Health Care Conference
Mar 1, 2018 01:03AM Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK
Mar 1, 2018 01:02AM Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK
Feb 27, 2018 09:00AM Amgen (AMGN) Receives Positive CHMP Opinion For Delivery System Of Neulasta
Feb 27, 2018 09:00AM Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim)
Feb 26, 2018 04:00PM Amgen (AMGN) to Present New Data From Repatha Clinical Trials At ACC.18
Feb 26, 2018 04:00PM Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18
Feb 23, 2018 08:22AM Amgen (AMGN) Obtains Positive CHMP Opinion on Expanded Use Of XGEVA
Feb 23, 2018 08:20AM Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Feb 14, 2018 04:01PM Amgen (AMGN) Reports FDA Advisory Committee Meeting to Review Potential New Use Of BLINCYTO
Feb 14, 2018 04:00PM Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)
Feb 8, 2018 06:44PM Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
Feb 8, 2018 04:00PM Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference
Feb 1, 2018 04:01PM Amgen Reports Fourth Quarter And Full Year 2017 Financial Results
Jan 30, 2018 09:01AM Amgen (AMGN) Reports CHMP Positive Opinion to Add Updated OS Data to KYPROLIS Label
Jan 30, 2018 09:00AM Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label
Jan 29, 2018 04:00PM Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results
Jan 22, 2018 04:32PM Amgen (AMGN) Says Aimovig Met All Primary And Secondary Endpoints in Unique Phase 3b Study In Episodic Migraine Patients
Jan 22, 2018 04:30PM Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments
Jan 18, 2018 04:01PM Amgen (AMGN) and Allergan's (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC
Jan 18, 2018 04:00PM European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Jan 17, 2018 04:22PM Amgen (AMGN) Says FDA Approved Addition of OS Data to KYPROLIS Label
Jan 17, 2018 04:15PM FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
Jan 17, 2018 04:11PM Amgen (AMGN) Reports Published OS Analysis from KYPROLIS (Carfilzomib) Phase 3 ASPIRE Trial
Jan 17, 2018 04:09PM Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
Jan 9, 2018 05:49AM Amgen (AMGN) Reports New Companion Diagnostic Agreement with Biocartis Group for Novel Oncology Compound
Jan 9, 2018 01:01AM Biocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound
Jan 8, 2018 06:17AM Amgen (AMGN) & UCB Announces European Medicines Agency Acceptance of Filing EVENITY (Romosozumab)
Jan 8, 2018 01:00AM European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)
Jan 5, 2018 09:01AM Amgen (AMGN) Granted FDA Approval for XGEVA (denosumab)
Jan 5, 2018 09:00AM FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Jan 4, 2018 04:00PM Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference
Dec 14, 2017 04:00PM Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
Dec 12, 2017 04:00PM Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
Dec 11, 2017 04:03PM Amgen (AMGN) Says KYPROLIS Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Dec 11, 2017 04:00PM KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Dec 11, 2017 09:00AM Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
Dec 7, 2017 09:08AM Amgen (AMGN) Says New Data to be Presented at ASH 2017 Underscore its Commitment to Patients With Difficult-To-Treat Blood Cancers
Dec 7, 2017 09:00AM New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Dec 6, 2017 04:00PM Amgen To Webcast Investor Call At ASH 2017
Dec 4, 2017 01:00AM Biocartis Group NV: Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests
Dec 1, 2017 04:01PM Amgen (AMGN) Announces FDA Approval of Repatha to Prevent Heart Attack And Stroke
Dec 1, 2017 04:00PM FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke
View More Recent Stories View Older Stories